Screening for neurofibromatosis type 1-related optic pathway gliomas: a systematic review.

Can J OphthalmolJul 2, 2026 (epub)
Clinical ResearchMedical GeneticsOphthalmologyRadiology (Diagnostic)

Abdullrahman Alshehri, Mohammed Almutairi, Mishari Alqahtani et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined the prevalence and clinical spectrum of optic pathway gliomas (OPGs) in patients with neurofibromatosis type 1 (NF1). Among 4,739 NF1 patients, 818 had OPGs, with a prevalence of 4.2% to 46.7%. The median age at OPG diagnosis was 29-58 months, highlighting the need for early screening.

Key findings

  • OPG prevalence in NF1 patients ranged from 4.2% to 46.7%.
  • Median age at OPG diagnosis was 29-58 months.
  • Approximately 58.4% of OPGs were asymptomatic.
  • Decreased visual acuity was reported in 62% of symptomatic patients.

Why it matters

Understanding the prevalence and early presentation of OPGs in NF1 patients is crucial for timely diagnosis and management, potentially preventing visual impairment through early screening.

Source

PubMed · PMID 42150614

Published in Can J Ophthalmol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Medical Genetics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.